Back to results
US 11,236,159 B2Granted
Methods of treating FGF21-associated disorders
AssigneeNovartis AG
InventorsBrian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Claims8
An isolated antibody or antigen-binding fragment thereof that specifically binds to the β-klotho sequence (SEQ ID NO:
- 262), and said antibody or antigen-binding fragment thereof comprises one of:
- (i) a heavy chain variable region comprising three heavy chain CDRs, wherein the three heavy chain CDRs comprise SEQ ID NOS:
- 23, 24, and 25, and a light chain variable region comprising three light chain CDRs, wherein the three light chain CDRs comprise SEQ ID NOS:
- 33, 34, and 35;
- (ii) a heavy chain variable region comprising three heavy chain CDRs, wherein the three heavy chain CDRs comprise SEQ ID NOS:
- 26, 27, and 28, and a light chain variable region comprising three light chain CDRs, wherein the three light chain CDRs comprise SEQ ID NOS:
- 36, 37, and 38;
- (iii) a heavy chain variable region comprising three heavy chain CDRs, wherein the three heavy chain CDRs comprise SEQ ID NOS:
- 268, 24, and 25, and a light chain variable region comprising three light chain CDRs, wherein the three light chain CDRs comprise SEQ ID NOS:
- 33, 34, and 35;
- and
- (iv) a heavy chain variable region comprising three heavy chain CDRs, wherein the three heavy chain CDRs comprise SEQ ID NOS:
- 269, 270, and 271, and a light chain variable region comprising three light chain CDRs, wherein the three light chain CDRs comprise SEQ ID NOS:
- 272, 273, and 35.
11 more elements
Dependencies are inferred from the claim text.